KPTI

KPT-9274

Cancer

Phase 1

Exp Date

TBD

Amp Volatility Score

Catalyst Info & Data Links

Potential Catalyst Events

  • TBA


From 2019 10K: "as well as our oral dual PAK4/NAMPT inhibitor, KPT-9274. ... We began clinical testing of KPT-9274 in patients with hematologic or solid tumors during 2016 and we plan to study its combination with an anti-PD1 monoclonal antibody in a phase 1 clinical study in the near future"



HC updated 5/22/20

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon